STOCK TITAN

Immune Therapeutics Inc - IMUND STOCK NEWS

Welcome to our dedicated news page for Immune Therapeutics (Ticker: IMUND), a resource for investors and traders seeking the latest updates and insights on Immune Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Immune Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Immune Therapeutics's position in the market.

Rhea-AI Summary
Biostax Corp announces the passing of H. Louis Salomonksy, a dedicated member of its Board of Directors. Biostax expresses condolences and plans for a smooth transition.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.45%
Tags
none
-
Rhea-AI Summary
Biostax Corp. announces research collaboration with Immgenuity, focusing on immunotherapies for HIV treatment. Joint research will determine if Biostax's drug therapies combined with Immgenuity's IMTV014 can achieve remission. Biostax's naltrexone-based drug candidates expected to work synergistically with the vaccine platform. Biostax also plans to fast track a Phase 2b trial with FDA for JKB-122 and Lodonalâ„¢ to decrease comorbidities and opportunistic infections in HIV patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Biostax Corp. (OTC Pink: IMUN) has finalized the transfer of three Investigational New Drug Applications (IND) for the drug candidate, JKB-122, from TaiwanJ Pharmaceuticals. The U.S. Food and Drug Administration (FDA) has approved the transfers, including INDs for the treatment of NASH, NAFLD, and Autoimmune Hepatitis. JKB-122 is a TLR4 antagonist targeting autoimmune and inflammatory conditions in chronic liver diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
Immune Therapeutics Inc

OTC:IMUND

IMUND Rankings

IMUND Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Winter Park